PDF herunterladen
Pneumologie 2008; 62(1): 23-30
DOI: 10.1055/s-2007-980131
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Medikamentöse Therapie des kleinzelligen Bronchialkarzinoms (SCLC) - neue molekulare Therapieansätze

Drug Therapy for Small-Cell Lung Cancer (SCLC) - New Molecular Strategies for TherapyW.  M.  Brückl1 , S.  Lampert1 , S.  Zirlik1 , E.  G.  Hahn1 , G.  H.  Wiest2
  • 1Medizinische Klinik 1 (Direktor: Prof. Dr. med. E. G. Hahn) Universitätsklinikum Erlangen
  • 2Lungenabteilung, Thoraxzentrum Hamburg (Chefarzt: PD Dr. med. G.H. Wiest) Asklepios Klinik Harburg
Weitere Informationen

Publikationsverlauf

eingereicht 1.8.2007

akzeptiert 4.9.2007

Publikationsdatum:
18. Oktober 2007 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Kleinzellige Bronchialkarzinome (SCLC) sind mit einem Anteil von etwa 20 % die aggressivsten Lungentumore. Obwohl sie zunächst gut auf Chemotherapeutika ansprechen, sind sie schnell wieder progredient und ihre Prognose hat sich daher auch nach über dreißig Jahren intensiver Forschung nicht wesentlich verbessert. Durch das molekulare Verständnis der Tumorentstehung und der maßgeblich beteiligten Gene beim SCLC könnten sich aber für die Zukunft interessante neue therapeutische Ansatzpunkte in Form von Antikörpern, kleinen Molekülen oder Vakzinierungen ergeben. Nach einer kurzen Einleitung über die Funktion des jeweiligen Gens wird dessen klinische Bedeutung beim SCLC erläutert. Hier soll zunächst die diagnostische und prognostische Bedeutung beleuchtet werden. Anschließend werden die aktuellen therapeutischen Ansätze, die sich häufig noch auf dem Level von klinischen Phase-I- und -II-Studien befinden, vorgestellt und bewertet.

Abstract

Small-cell lung cancer accounts for up to 20 % of lung cancer and is the most aggressive type. Although responding to chemotherapy, it often relapses early. In spite of more than thirty years of intensive research, its prognosis has not been inproved. Through increasing knowledge about molecular mechanisms and the involved genes, translational research into antibodies, small molecules and even vaccines, might result in interesting new strategies for the near future. After a short introduction about the function of the relevant genes, the diagnostic and prognostic value will be described. In the second part of this review the focus will lie on current studies (mostly phases I and II) for the treatment of SCLC.

Literatur

  • 1 Jemal A, Tiwari R C, Murray T. et al . Cancer statistics, 2004.  CA Cancer J Clin. 2004;  54 8-29
    Google Scholar
  • 2 Tyczynski J E, Bray F, Parkin D M. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection.  Lancet Oncol. 2003;  4 45-55
    Google Scholar
  • 3 Brueckl W M, Herbst L, Lechler A. et al . Predictive and prognostic factors in small cell lung carcinoma (SCLC) - analysis from routine clinical practice.  Anticancer Res. 2006;  26 4825-4832
    Google Scholar
  • 4 Turrisi 3rd A T, Kim K, Blum R. et al . Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.  N Engl J Med. 1999;  340 265-271
    Google Scholar
  • 5 Auperin A, Arriagada R, Pignon J P. et al . Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.  N Engl J Med. 1999;  341 476-484
    Google Scholar
  • 6 Sundstrom S, Bremnes R M, Kaasa S. et al . Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up.  J Clin Oncol. 2002;  20 4665-7462
    Google Scholar
  • 7 Slotman B, Faivre-Finn C, Kramer G. et al . A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08 993-22 993).  Proc Am Soc Clin Oncol. 2007;  25 2s
    Google Scholar
  • 8 Pawel J von, Schiller J H, Shepherd F A. et al . Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.  J Clin Oncol. 1999;  17 658-667
    Google Scholar
  • 9 Chute J P, Chen T, Feigal E. et al . Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.  J Clin Oncol. 1999;  17 1794-1801
    Google Scholar
  • 10 Schmidt E V. The role of c-myc in regulation of translation initiation.  Oncogene. 2004;  23 3217-3221
    Google Scholar
  • 11 Ponzielli R, Katz S, Barsyte-Lovejoy D. et al . Cancer therapeutics: targeting the dark side of Myc.  Eur J Cancer. 2005;  41 2485-2501
    Google Scholar
  • 12 Akie K, Dosaka-Akita H, Murakami A. et al . A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer.  Antisense Nucleic Acid Drug Dev. 2000;  10 243-249
    Google Scholar
  • 13 Devi G R, Beer T M, Corless C L. et al . In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.  Clin Cancer Res. 2005;  11 3930-3938
    Google Scholar
  • 14 de Jong D, Prins F A, Mason D Y. et al . Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells.  Cancer Res. 1994;  54 256-2560
    Google Scholar
  • 15 Reed J C. Bcl-2 family proteins.  Oncogene. 1998;  17 3225-3236
    Google Scholar
  • 16 Ben-Ezra J M, Kornstein M J, Grimes M M. et al . Small cell carcinomas of the lung express the Bcl-2 protein.  Am J Pathol. 1994;  145 1036-1040
    Google Scholar
  • 17 Fennell D A. Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer.  Clin Lung Cancer. 2003;  4 307-313
    Google Scholar
  • 18 Higashiyama M, Doi O, Kodama K. et al . Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer.  Tumour Biol. 1996;  17 341-344
    Google Scholar
  • 19 Ikegaki N, Katsumata M, Minna J. et al . Expression of bcl-2 in small cell lung carcinoma cells.  Cancer Res. 1994;  54 6-8
    Google Scholar
  • 20 Paik K H, Park Y H, Ryoo B Y. et al . Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer.  J Korean Med Sci. 2006;  21 35-39
    Google Scholar
  • 21 Maitra A, Amirkhan R H, Saboorian M H. et al . Survival in small cell lung carcinoma is independent of Bcl-2 expression.  Hum Pathol. 1999;  30 712-717
    Google Scholar
  • 22 Breton C, Story M D, Meyn R E. Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell lung cancer cell lines treated with etoposide.  Anticancer Drugs. 1998;  9 751-757
    Google Scholar
  • 23 Kim Y C, Park K O, Kern J A. et al . The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.  Lung Cancer. 1998;  22 181-190
    Google Scholar
  • 24 Sartorius U A, Krammer P H. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.  Int J Cancer. 2002;  97 584-592
    Google Scholar
  • 25 Zangemeister-Wittke U, Schenker T, Luedke G H. et al . Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.  Br J Cancer. 1998;  78 1035-1042
    Google Scholar
  • 26 Rudin C M, Kozloff M, Hoffman P C. et al . Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.  J Clin Oncol. 2004;  22 1110-1117
    Google Scholar
  • 27 Rudin C M, Salgia R, Wang X F. et al . CALGB30103: A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC).  Proc Am Soc Clin Oncol. 2005;  23 7168
    Google Scholar
  • 28 Mortenson M M, Schlieman M G, Virudachalam S. et al . Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.  Lung Cancer. 2005;  49 163-170
    Google Scholar
  • 29 Richardson P G, Sonneveld P, Schuster M W. et al . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.  N Engl J Med. 2005;  352 2487-2498
    Google Scholar
  • 30 Lara P N, Chansky C, Davies A M. et al . Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: A Southwest Oncology Group Phase II Trial (S0327).  Journal of Thoracic Oncology. 2006;  1 996-1001
    Google Scholar
  • 31 Tomita M, Wright J J, Kellogg R. Phase I study of topotecan and brotezomib (Vc) with pharmacokinetic and pharmacodynamic correlates.  Lung Cancer. 2005;  49 798
    Google Scholar
  • 32 Levine A J, Momand J, Finlay C A. The p53 tumour suppressor gene.  Nature. 1991;  351 453-456
    Google Scholar
  • 33 Olivier M, Eeles R, Hollstein M. et al . The IARC TP53 database: new online mutation analysis and recommendations to users.  Hum Mutat. 2002;  19 607-614
    Google Scholar
  • 34 Denissenko M F, Pao A, Tang M. et al . Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.  Science. 1996;  274 430-432
    Google Scholar
  • 35 Vaart P J van de, Belderbos J, de Jong D. et al . DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy.  Int J Cancer. 2000;  89 160-166
    Google Scholar
  • 36 Cagini L, Monacelli M, Giustozzi G. et al . Biological prognostic factors for early stage completely resected non-small cell lung cancer.  J Surg Oncol. 2000;  74 53-60
    Google Scholar
  • 37 Rosenfeld M R, Malats N, Schramm L. et al . Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.  J Natl Cancer Inst. 1997;  89 381-385
    Google Scholar
  • 38 Zalcman G, Tredaniel J, Schlichtholz B. et al . Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer.  Int J Cancer. 2000;  89 81-86
    Google Scholar
  • 39 Rodriguez-Salas N, Palacios J, Moreno G. et al . Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas.  Lung Cancer. 2001;  34 67-74
    Google Scholar
  • 40 Gemba K, Ueoka H, Kiura K. et al . Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome.  Lung Cancer. 2000;  29 23-31
    Google Scholar
  • 41 Antonia S J, Mirza N, Fricke I. et al . Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.  Clin Cancer Res. 2006;  12 878-887
    Google Scholar
  • 42 Chiappori A, Sereno M, Gabrilovich D I. et al . Phase II trial of patients with extensive stage small cell lung cancer (ES-SCLC) immunized with p53-transduced dendritic cells (p53-DC): Immune sensitization to chemotherapy.  Proc Am Soc Clin Oncol. 2007;  25 120s
    Google Scholar
  • 43 Cantley L C, Neel B G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.  Proc Natl Acad Sci U S A. 1999;  96 4240-4245
    Google Scholar
  • 44 Liaw D, Marsh D J, Li J. et al . Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.  Nat Genet. 1997;  16 64-67
    Google Scholar
  • 45 Nelen M R, Staveren W C van, Peeters E A. et al . Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.  Hum Mol Genet. 1997;  6 1383-1387
    Google Scholar
  • 46 Forgacs E, Biesterveld E J, Sekido Y. et al . Mutation analysis of the PTEN/MMAC1 gene in lung cancer.  Oncogene. 1998;  17 1557-1565
    Google Scholar
  • 47 Virmani A K, Fong K M, Kodagoda D. et al . Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types.  Genes Chromosomes Cancer. 1998;  21 308-319
    Google Scholar
  • 48 Kim S K, Su L K, Oh Y. et al . Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.  Oncogene. 1998;  16 89-93
    Google Scholar
  • 49 Kohno T, Takahashi M, Manda R. et al . Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers.  Genes Chromosomes Cancer. 1998;  22 152-156
    Google Scholar
  • 50 Yokomizo A, Tindall D J, Drabkin H. et al . PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers.  Oncogene. 1998;  17 475-479
    Google Scholar
  • 51 Shi Y, Gera J, Hu L. et al . Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.  Cancer Res. 2002;  62 5027-5034
    Google Scholar
  • 52 Pandya K J, Levy D E, Hidalgo M. et al . A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A prelimanry report.  Proc Am Soc Clin Oncol. 2005;  23 LBA 7005
    Google Scholar
  • 53 Molenaar W M, de Leij L, Trojanowski J Q. Neuroectodermal tumors of the peripheral and the central nervous system share neuroendocrine N-CAM-related antigens with small cell lung carcinomas.  Acta Neuropathol (Berl). 1991;  83 46-54
    Google Scholar
  • 54 Rutishauser U, Acheson A, Hall A K. et al . The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions.  Science. 1988;  240 53-57
    Google Scholar
  • 55 Lantuejoul S, Moro D, Michalides R J. et al . Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors.  Am J Surg Pathol. 1998;  22 1267-1276
    Google Scholar
  • 56 Kibbelaar R E, Moolenaar K E, Michalides R J. et al . Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma.  Eur J Cancer. 1991;  27 431-435
    Google Scholar
  • 57 Kontogianni K, Nicholson A G, Butcher D. et al . CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefact.  J Clin Pathol. 2005;  58 978-980
    Google Scholar
  • 58 Tassone P, Gozzini A, Goldmacher V. et al . In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.  Cancer Res. 2004;  64 4629-4636
    Google Scholar
  • 59 Fosella F, McCann J, Tolcher A. et al . Phase II trial of BB-10 901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma.  Proc Am Soc Clin Oncol. 2005;  23 7159
    Google Scholar
  • 60 Allsopp R C, Vaziri H, Patterson C. et al . Telomere length predicts replicative capacity of human fibroblasts.  Proc Natl Acad Sci U S A. 1992;  89 10 114-10 118
    Google Scholar
  • 61 Harley C B, Futcher A B, Greider C W. Telomeres shorten during ageing of human fibroblasts.  Nature. 1990;  345 458-460
    Google Scholar
  • 62 Hastie N D, Dempster M, Dunlop M G. et al . Telomere reduction in human colorectal carcinoma and with ageing.  Nature. 1990;  346 866-868
    Google Scholar
  • 63 Meyerson M. Role of telomerase in normal and cancer cells.  J Clin Oncol. 2000;  18 2626-2634
    Google Scholar
  • 64 Counter C M, Avilion A A, LeFeuvre C E. et al . Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity.  Embo J. 1992;  11 1921-1929
    Google Scholar
  • 65 Holt S E, Shay J W. Role of telomerase in cellular proliferation and cancer.  J Cell Physiol. 1999;  180 10-18
    Google Scholar
  • 66 Nakamura T M, Cech T R. Reversing time: origin of telomerase.  Cell. 1998;  92 587-590
    Google Scholar
  • 67 Sarvesvaran J, Going J J, Milroy R. et al . Is small cell lung cancer the perfect target for anti-telomerase treatment?.  Carcinogenesis. 1999;  20 1649-1651
    Google Scholar
  • 68 Lantuejoul S, Soria J C, Moro-Sibilot D. et al . Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours.  Br J Cancer. 2004;  90 1222-1229
    Google Scholar
  • 69 Osaki T, Oyama T, Inoue M. et al . Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications.  Jpn J Thorac Cardiovasc Surg. 2001;  49 545-551
    Google Scholar
  • 70 Hiyama K, Hiyama E, Ishioka S. et al . Telomerase activity in small-cell and non-small-cell lung cancers.  J Natl Cancer Inst. 1995;  87 895-902
    Google Scholar
  • 71 Song J S. Adenovirus-mediated suicide SCLC gene therapy using the increased activity of the hTERT promoter by the MMRE and SV40 enhancer.  Biosci Biotechnol Biochem. 2005;  69 56-62
    Google Scholar
  • 72 Song J S, Kim H P. Adenovirus-mediated HSV-TK gene therapy using the human telomerase promoter induced apoptosis of small cell lung cancer cell line.  Oncol Rep. 2004;  12 443-447
    Google Scholar
  • 73 Brunsvig P F, Gjertsen M K, Kvalheim G. et al . A phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer.  Proc Am Soc Clin Oncol. 2005;  23 2580
    Google Scholar
  • 74 Grotzinger J. Molecular mechanisms of cytokine receptor activation.  Biochim Biophys Acta. 2002;  1592 2152-23
    Google Scholar
  • 75 Blackhall F H, Pintilie M, Michael M. et al . Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.  Clin Cancer Res. 2003;  9 2241-2247
    Google Scholar
  • 76 Hasegawa Y, Takanashi S, Okudera K. et al . Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients.  Intern Med. 2005;  44 26-34
    Google Scholar
  • 77 Micke P, Hengstler J G, Ros R. et al . c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis.  Int J Cancer. 2001;  92 474-479
    Google Scholar
  • 78 Potti A, Willardson J, Forseen C. et al . Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma.  Lung Cancer. 2002;  36 257-261
    Google Scholar
  • 79 Rohr U P, Rehfeld N, Pflugfelder L. et al . Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer.  Int J Cancer. 2004;  111 259-263
    Google Scholar
  • 80 Taniwaki M, Daigo Y, Ishikawa N. et al . Gene expression profiles of small-cell lung cancers: Molecular signatures of lung cancer.  Int J Oncol. 2006;  29 567-575
    Google Scholar
  • 81 Volm M, Koomagi R, Mattern J. et al . Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro.  Anticancer Res. 1997;  17 99-103
    Google Scholar
  • 82 Fabbro D, Ruetz S, Buchdunger E. et al . Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.  Pharmacol Ther. 2002;  93 79-98
    Google Scholar
  • 83 Franklin W A, Veve R, Hirsch F R. et al . Epidermal growth factor receptor family in lung cancer and premalignancy.  Semin Oncol. 2002;  29 3-14
    Google Scholar
  • 84 Wells A. EGF receptor.  Int J Biochem Cell Biol. 1999;  31 637-643
    Google Scholar
  • 85 Gamou S, Hunts J, Harigai H. et al . Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cells.  Cancer Res. 1987;  47 2668-2673
    Google Scholar
  • 86 Shigematsu H, Lin L, Takahashi T. et al . Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.  J Natl Cancer Inst. 2005;  97 339-346
    Google Scholar
  • 87 Tanno S, Toyoshima E, Kikuchi K. ZD 1839 inhibited ERK1/2 phosphorylation induced by EGF in small cell lung cancer cell lines with deetectable and undetectable EGFR expression.  Proc Am Assoc Cancer Res. 2003;  44 6558
    Google Scholar
  • 88 Araki J, Okamoto I, Suto R. et al . Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.  Lung Cancer. 2005;  48 141-144
    Google Scholar
  • 89 Okamoto I, Araki J, Suto R. et al . EGFR mutation in gefitinib-responsive small-cell lung cancer.  Ann Oncol. 2006;  17 1028-1029
    Google Scholar
  • 90 Zakowski M F, Ladanyi M, Kris M G. EGFR mutations in small-cell lung cancers in patients who have never smoked.  N Engl J Med. 2006;  355 213-155
    Google Scholar
  • 91 Moore A M, Estes D, Govidan R. et al . A phase II trial of gefitinib in patients with chemosensitive and chemorefractory relapsed neuroendocrine cancers. A Hoosier Oncology Group Trial.  Proc Am Soc Clin Oncol. 2005;  23 7160
    Google Scholar
  • 92 Lynch T J, Bell D W, Sordella R. et al . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2004;  350 2129-2139
    Google Scholar
  • 93 Paez J G, Janne P A, Lee J C. et al . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.  Science. 2004;  304 1497-1500
    Google Scholar
  • 94 Pao W, Miller V, Zakowski M. et al . EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib.  Proc Natl Acad Sci U S A. 2004;  101 13 306-13 311
    Google Scholar
  • 95 Shepherd F A, Rodrigues Pereira J, Ciuleanu T. et al . Erlotinib in previously treated non-small-cell lung cancer.  N Engl J Med. 2005;  353 123-132
    Google Scholar
  • 96 Tsao M S, Sakurada A, Cutz J C. et al . Erlotinib in lung cancer - molecular and clinical predictors of outcome.  N Engl J Med. 2005;  353 133-144
    Google Scholar
  • 97 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor.  Endocr Rev. 1997;  18 4-25
    Google Scholar
  • 98 Ogawa S, Oku A, Sawano A. et al . A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain.  J Biol Chem. 1998;  273 31 273-31 282
    Google Scholar
  • 99 Neufeld G, Cohen T, Gengrinovitch S. et al . Vascular endothelial growth factor (VEGF) and its receptors.  Faseb J. 1999;  13 9-22
    Google Scholar
  • 100 Veikkola T, Karkkainen M, Claesson-Welsh L. et al . Regulation of angiogenesis via vascular endothelial growth factor receptors.  Cancer Res. 2000;  60 203-212
    Google Scholar
  • 101 Presta L G, Chen H, O'Connor S J. et al . Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.  Cancer Res. 1997;  57 4593-4599
    Google Scholar
  • 102 Raefsky E L, Spigel D R, Greco F A. et al . Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network.  Proc Am Soc Clin Oncol. 2005;  23 7050
    Google Scholar
  • 103 Ready N, Dudek A Z, Wang X F. et al . CALGB 30 306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive sage small cell lung cancer (ES-SCLC).  Proc Am Soc Clin Oncol. 2007;  25 400s
    Google Scholar
  • 104 Hibi K, Takahashi T, Sekido Y. et al . Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer.  Oncogene. 1991;  6 2291-2296
    Google Scholar
  • 105 Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts.  Br J Cancer. 1993;  67 37-46
    Google Scholar
  • 106 Sekido Y, Obata Y, Ueda R. et al . Preferential expression of c-kit protooncogene transcripts in small cell lung cancer.  Cancer Res. 1991;  51 2416-2419
    Google Scholar
  • 107 Wang W L, Healy M E, Sattler M. et al . Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.  Oncogene. 2000;  19 3521-3528
    Google Scholar
  • 108 Soria J C, Johnson B E, Chevalier T L. Imatinib in small cell lung cancer.  Lung Cancer. 2003;  41 Suppl 1 S49-53
    Google Scholar
  • 109 Johnson B E, Fischer T, Fischer B. et al . Phase II study of imatinib in patients with small cell lung cancer.  Clin Cancer Res. 2003;  9 5880-5887
    Google Scholar
  • 110 Dy G K, Miller A A, Mandrekar S. A phase II NCCTG/CALGB trial of imatinib (STI571) in patietns with c-kit expressing relapsed small cell lung cancer (SCLC).  Proc Am Assoc Cancer Res. 2005;  23 632s
    Google Scholar
  • 111 Mendel D B, Laird A D, Xin X. et al . In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.  Clin Cancer Res. 2003;  9 327-337
    Google Scholar
  • 112 Kulke M, Lenz H, Meropol N. A phse 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumours.  Proc Am Assoc Cancer Res. 2005;  23 310s
    Google Scholar
  • 113 Wilhelm S M, Carter C, Tang L. et al . BAY 43 - 9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.  Cancer Res. 2004;  64 7099-7109
    Google Scholar
  • 114 Ryan A J, Wedge S R. ZD6747: a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.  Br J Cancer. 2005;  92 S6-S13
    Google Scholar
  • 115 Arnold A M, Smylie M, Ding K. et al . Randomized phase II study of maintanance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20.  Proc Am Soc Clin Oncol. 2007;  25 390s
    Google Scholar
  • 116 Bhattacharjee A, Richards W G, Staunton J. et al . Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.  Proc Natl Acad Sci U S A. 2001;  98 13 790-13 795
    Google Scholar
  • 117 Garber M E, Troyanskaya O G, Schluens K. et al . Diversity of gene expression in adenocarcinoma of the lung.  Proc Natl Acad Sci U S A. 2001;  98 13 784-13 789
    Google Scholar
  • 118 Sugita M, Geraci M, Gao B. et al . Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.  Cancer Res. 2002;  62 3971-3979
    Google Scholar
  • 119 Coonney M M, Subbiah S, Chapman R. Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission.  Proc Am Assoc Cancer Res. 2005;  23 661s
    Google Scholar

PD Dr. med. Wolfgang M. Brückl

Leiter der pneumologischen Onkologie, Medizinische Klinik 1, Universitätsklinikum Erlangen

Ulmenweg 18

91054 Erlangen

eMail: wolfgang.brueckl@uk-erlangen.de